Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue from External Customer [Line Items]
Revenues	[1]	$ 81,288	$ 41,651	$ 40,905
Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[1],[2]	79,557	40,724	38,013
Pfizer CentreOne [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	1,731	926	810
BioNTech [Member] | Pfizer CentreOne [Member]
Revenue from External Customer [Line Items]
Revenues		320	0	0
Alliance Biopharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues		7,652	5,418	4,648
Total Biosimilars [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	2,343	1,527	911
Total Sterile Injectable Pharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	5,746	5,315	5,013
Vaccines [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		42,625	6,575	6,504
Vaccines [Member] | Comirnaty direct sales and alliance revenues [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		36,781	154	0
Vaccines [Member] | Prevenar 13/Prevnar 13 [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[5]	5,272	5,850	5,847
Vaccines [Member] | Nimenrix [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		193	221	230
Vaccines [Member] | FSME/IMMUN-TicoVac [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		185	196	220
Vaccines [Member] | Trumenba [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		118	112	135
Vaccines [Member] | Other Vaccines Products [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		74	42	73
Oncology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		12,333	10,867	9,014
Oncology [Member] | Ibrance [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		5,437	5,392	4,961
Oncology [Member] | Xtandi Alliance Revenues [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,185	1,024	838
Oncology [Member] | Inlyta [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,002	787	477
Oncology [Member] | Sutent [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		673	819	936
Oncology [Member] | Bosulif [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		540	450	365
Oncology [Member] | Xalkori [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		493	544	530
Oncology [Member] | Ruxience [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	491	170	(1)
Oncology [Member] | Retacrit [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	444	386	225
Oncology [Member] | Zirabev [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	444	143	1
Oncology [Member] | Lorbrena [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		266	204	115
Oncology [Member] | Aromasin [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		211	148	136
Oncology [Member] | Trazimera [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	197	98	6
Oncology [Member] | Besponsa [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		192	182	157
Oncology [Member] | Braftovi [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		187	160	48
Oncology [Member] | Bavencio Alliance Revenues [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		178	80	49
Oncology [Member] | Mektovi [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		155	142	49
Oncology [Member] | Other Oncology Products [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		238	137	122
Internal Medicine [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		9,329	9,003	8,790
Internal Medicine [Member] | Eliquis [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		5,970	4,949	4,220
Internal Medicine [Member] | Premarin Family [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		563	680	734
Internal Medicine [Member] | Chantix Champix [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		398	919	1,107
Internal Medicine [Member] | BMP2 [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		266	274	287
Internal Medicine [Member] | Toviaz [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		238	252	250
Internal Medicine [Member] | Pristiq [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		187	171	176
Internal Medicine [Member] | All Other Internal Medicine [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,706	1,758	2,016
Hospital [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[1]	7,301	6,777	6,695
Hospital [Member] | Sulperazon [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		683	618	684
Hospital [Member] | Medrol [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		432	402	469
Hospital [Member] | Zavicefta [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		413	212	108
Hospital [Member] | Fragmin [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		305	252	253
Hospital [Member] | Zithromax Zmax [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		278	276	336
Hospital [Member] | Vfend [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		267	270	346
Hospital [Member] | Tygacil [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		200	160	197
Hospital [Member] | Precedex [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		177	260	155
Hospital [Member] | Zyvox [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		173	222	251
Hospital [Member] | Paxlovid [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		76	0	0
Hospital [Member] | IVIg Products [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[6]	430	376	275
Hospital [Member] | Other Anti-infectives [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,453	1,294	1,396
Hospital [Member] | Other Hospital Products [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		2,412	2,435	2,225
Inflammation and Immunology [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		4,431	4,567	4,733
Inflammation and Immunology [Member] | Xeljanz [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		2,455	2,437	2,242
Inflammation and Immunology [Member] | Enbrel [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		1,185	1,350	1,699
Inflammation and Immunology [Member] | Inflectra/Remsima [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	657	659	625
Inflammation and Immunology [Member] | All Other Inflammation and Immunology Products [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		134	121	167
Rare Disease [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		3,538	2,936	2,278
Rare Disease [Member] | Vyndaqel/Vyndamax [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		2,015	1,288	473
Rare Disease [Member] | BeneFIX [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		438	454	488
Rare Disease [Member] | Genotropin [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		389	427	498
Rare Disease [Member] | ReFacto AF Xyntha [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		304	370	426
Rare Disease [Member] | Somavert [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		277	277	264
Rare Disease [Member] | All Other Rare Disease Products [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Revenues		115	120	129
Consumer Healthcare Reporting Unit [Member]
Revenue from External Customer [Line Items]
Revenues	[7]	$ 0	$ 0	$ 2,082

[1] On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. On November 16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. On December 21, 2020, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration. Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations for all periods presented. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and Mylan-Japan collaboration were reflected as discontinued operations for all periods presented. Prior-period financial information has been restated, as appropriate. See Note 1A.

[2] At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($320 million for 2021 and $0 million for 2020 and 2019), and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior period information to conform to the current management structure.

[3] Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Ruxience, Retacrit, Zirabev and Trazimera.

[4] Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.

[5] Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20 (adult).

[6] Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig.

[7] On July 31, 2019, our Consumer Healthcare business, an OTC medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare JV. See Note 2C.